GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Days Payable

ProPhase Labs (ProPhase Labs) Days Payable

: 103.36 (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

ProPhase Labs's average Accounts Payable for the three months ended in Dec. 2023 was $7.43 Mil. ProPhase Labs's Cost of Goods Sold for the three months ended in Dec. 2023 was $6.56 Mil. Hence, ProPhase Labs's Days Payable for the three months ended in Dec. 2023 was 103.36.

The historical rank and industry rank for ProPhase Labs's Days Payable or its related term are showing as below:

PRPH' s Days Payable Range Over the Past 10 Years
Min: 21.84   Med: 57.91   Max: 179.36
Current: 78.87

During the past 13 years, ProPhase Labs's highest Days Payable was 179.36. The lowest was 21.84. And the median was 57.91.

PRPH's Days Payable is ranked better than
55.92% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: 70.14 vs PRPH: 78.87

ProPhase Labs's Days Payable increased from Dec. 2022 (32.25) to Dec. 2023 (103.36). It may suggest that ProPhase Labs delayed paying its suppliers.


ProPhase Labs Days Payable Historical Data

The historical data trend for ProPhase Labs's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.84 77.42 53.18 45.39 99.13

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Payable Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.25 55.95 65.06 77.47 103.36

Competitive Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs Days Payable Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Days Payable distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Days Payable falls into.



ProPhase Labs Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

ProPhase Labs's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (5.905 + 9.383) / 2 ) / 28.145*365
=7.644 / 28.145*365
=99.13

ProPhase Labs's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

Days Payable (Q: Dec. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2023 ) + Accounts Payable (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (5.467 + 9.383) / 2 ) / 6.555*365 / 4
=7.425 / 6.555*365 / 4
=103.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProPhase Labs Days Payable Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus